open access

Vol 55, No 1 (2021)
Invited Editorial
Submitted: 2020-10-16
Accepted: 2020-11-05
Published online: 2021-01-13
Get Citation

Melatonin secretion in migraine patients: the current state of knowledge

Daniel Zielonka1
·
Pubmed: 33438752
·
Neurol Neurochir Pol 2021;55(1):5-7.
Affiliations
  1. Department of Public Health, Poznan University of Medical Sciences, Poznan, Poland

open access

Vol 55, No 1 (2021)
Invited editorials
Submitted: 2020-10-16
Accepted: 2020-11-05
Published online: 2021-01-13

Abstract

Introduction. Zduńska et al. [1] present the results of a pilot study exploring changes in melatonin serum concentration in migraine patients, and the clinical implications of these changes.

Clinical reflections. Melatonin secretion may be altered for several reasons, and migraine is one of those clinical conditions where melatonin secretion can be changed. Correlations between migraine clinical phenotype and melatonin secretion pat-terns may bring exciting results.

Clinical implications. Alterations in melatonin secretion in migraine has not been explained. Studies which aim at exploring the mechanism(s) of action of melatonin secretion in migraine patients may provide an insight into the pathogenesis of migraine and contribute to effective treatment options.

Abstract

Introduction. Zduńska et al. [1] present the results of a pilot study exploring changes in melatonin serum concentration in migraine patients, and the clinical implications of these changes.

Clinical reflections. Melatonin secretion may be altered for several reasons, and migraine is one of those clinical conditions where melatonin secretion can be changed. Correlations between migraine clinical phenotype and melatonin secretion pat-terns may bring exciting results.

Clinical implications. Alterations in melatonin secretion in migraine has not been explained. Studies which aim at exploring the mechanism(s) of action of melatonin secretion in migraine patients may provide an insight into the pathogenesis of migraine and contribute to effective treatment options.

Get Citation

Keywords

melatonin, light, migraine

About this article
Title

Melatonin secretion in migraine patients: the current state of knowledge

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 55, No 1 (2021)

Article type

Invited Editorial

Pages

5-7

Published online

2021-01-13

Page views

881

Article views/downloads

990

DOI

10.5603/PJNNS.a2021.0002

Pubmed

33438752

Bibliographic record

Neurol Neurochir Pol 2021;55(1):5-7.

Keywords

melatonin
light
migraine

Authors

Daniel Zielonka

References (30)
  1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2163–2196.
  2. Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50s. J Headache Pain. 2016; 17(1): 104.
  3. Olsen J. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38(1): 1–211.
  4. Kreczmański P, Wolak T, Lewandowska M, et al. Altered functional brain imaging in migraine patients: BOLD preliminary study in migraine with and without aura. Neurol Neurochir Pol. 2019; 53(4): 304–310.
  5. Rościszewska-Żukowska I, Zając-Mnich M, Janik P. Characteristics and clinical correlates of white matter changes in brain magnetic resonance of migraine females. Neurol Neurochir Pol. 2018; 52(6): 695–703.
  6. Maniyar FH, Sprenger T, Schankin C, et al. Photic hypersensitivity in the premonitory phase of migraine--a positron emission tomography study. Eur J Neurol. 2014; 21(9): 1178–1183.
  7. Maniyar FH, Sprenger T, Monteith T, et al. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain. 2014; 137(Pt 1): 232–241.
  8. Mays JC, Kelly MC, Coon SL, et al. Single-cell RNA sequencing of the mammalian pineal gland identifies two pinealocyte subtypes and cell type-specific daily patterns of gene expression. PLoS One. 2018; 13(10): e0205883.
  9. Emens JS, Burgess HJ. Effect of Light and Melatonin and Other Melatonin Receptor Agonists on Human Circadian Physiology. Sleep Med Clin. 2015; 10(4): 435–453.
  10. Zielonka D, Sowiński J, Nowak S, et al. Melatonin and cortisol profiles in patients with pituitary tumors. Neurol Neurochir Pol. 2015; 49(1): 65–69.
  11. Kim JH, Duffy JF. Circadian Rhythm Sleep-Wake Disorders in Older Adults. Sleep Med Clin. 2018; 13(1): 39–50.
  12. Bettahi I, Pozo D, Osuna C, et al. Melatonin reduces nitric oxide synthase activity in rat hypothalamus. J Pineal Res. 1996; 20(4): 205–210.
  13. Zisapel N. Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cell Mol Neurobiol. 2001; 21(6): 605–616.
  14. Ramadan N. The Link Between Glutamate and Migraine. CNS Spectrums. 2014; 8(6): 446–449.
  15. Peres MFP, Masruha MR, Zukerman E, et al. Potential therapeutic use of melatonin in migraine and other headache disorders. Expert Opin Investig Drugs. 2006; 15(4): 367–375.
  16. Ansari M, Karkhaneh A, Kheirollahi A, et al. The effect of melatonin on gene expression of calcitonin gene-related peptide and some proinflammatory mediators in patients with pure menstrual migraine. Acta Neurol Belg. 2017; 117(3): 677–685.
  17. Singh M, Jadhav HR. Melatonin: functions and ligands. Drug Discov Today. 2014; 19(9): 1410–1418.
  18. Danilov A, Kurganova J, Kurganova JuM, et al. [Melatonin in chronic pain syndromes]. Zh Nevrol Psikhiatr Im S S Korsakova. 2015; 115(10 Pt 2): 47–54.
  19. Masruha MR, Lin J, de Souza Vieira DS, et al. Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities. Headache. 2010; 50(3): 413–419.
  20. Masruha MR, de Souza Vieira DS, Minett TS, et al. Low urinary 6-sulphatoxymelatonin concentrations in acute migraine. J Headache Pain. 2008; 9(4): 221–224.
  21. Long R, Zhu Y, Zhou S. Therapeutic role of melatonin in migraine prophylaxis: A systematic review. Medicine (Baltimore). 2019; 98(3): e14099.
  22. Claustrat B, Loisy C, Brun J, et al. Nocturnal plasma melatonin levels in migraine: a preliminary report. Headache. 1989; 29(4): 242–245.
  23. Murialdo G, Fonzi S, Costelli P, et al. Urinary melatonin excretion throughout the ovarian cycle in menstrually related migraine. Cephalalgia. 1994; 14(3): 205–209.
  24. Brun J, Claustrat B, Saddier P, et al. Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia. 1995; 15(2): 136–9; discussion 79.
  25. Peres MF, Sanchez del Rio M, Seabra ML, et al. Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry. 2001; 71(6): 747–751.
  26. Kozak HH, Boysan M, Uca AU, et al. Sleep quality, morningness-eveningness preference, mood profile, and levels of serum melatonin in migraine patients: a case-control study. Acta Neurol Belg. 2017; 117(1): 111–119.
  27. Claustrat B, Brun J, Geoffriau M, et al. Nocturnal plasma melatonin profile and melatonin kinetics during infusion in status migrainosus. Cephalalgia. 1997; 17(4): 511–7; discussion 487.
  28. Chądzyński P, Kacprzak A, Domitrz W, et al. Migraine headache facilitators in a population of Polish women and their association with migraine occurrence - preliminary results. Neurol Neurochir Pol. 2019; 53(5): 377–383.
  29. Salvesen R, Bekkelund SI. Migraine, as compared to other headaches, is worse during midnight-sun summer than during polar night. A questionnaire study in an Arctic population. Headache. 2000; 40(10): 824–829.
  30. Claustrat B, Brun J, Chiquet C, et al. Melatonin secretion is supersensitive to light in migraine. Cephalalgia. 2004; 24(2): 128–133.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl